DrugPatentWatch Database Preview
MYLERAN Drug Profile
or, see our see our flat-rate plans
Which patents cover Myleran, and when can generic versions of Myleran launch?
The generic ingredient in MYLERAN is busulfan. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the busulfan profile page.
Summary for MYLERAN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 72 |
| Clinical Trials: | 11 |
| Patent Applications: | 4,591 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MYLERAN at DailyMed |
Pharmacology for MYLERAN
| Drug Class | Alkylating Drug |
| Mechanism of Action | Alkylating Activity |
Medical Subject Heading (MeSH) Categories for MYLERAN
Synonyms for MYLERAN
| 1, {4-Bis[methanesulfonoxy]butane} |
| 1,{4-Bis[methanesulfonoxy]butane} |
| 1,4-Bis(methanesulfonoxy)butane |
| 1,4-Bis(methanesulfonyloxy)butane |
| 1,4-Bis[methanesulfonoxy]butane |
| 1,4-Butanedi yl dimethanesulfonate |
| 1,4-BUTANEDIOL DIMETHANESULFONATE |
| 1,4-Butanediol dimethanesulphonate |
| 1,4-Butanediol dimethylsulfonate |
| 1,4-Butanediol, dimethanesulfonate |
| 1,4-Butanediol, dimethanesulphonate |
| 1,4-butanedioldimethanesulfonate |
| 1,4-Butanediyl dimethanesulfonate |
| 1,4-Di(methylsulfonoxy)butane |
| 1,4-Dimesyloxybutane |
| 1,4-Dimethane sulfonyl oxybutane |
| 1,4-Dimethanesulfonoxybutane |
| 1,4-Dimethanesulfonoxylbutane |
| 1,4-Dimethanesulfonyloxybutane |
| 1,4-Dimethanesulphonyloxybutane |
| 1,4-Dimethylsulfonoxybutane |
| 1,4-Dimethylsulfonyloxybutane |
| 15167-EP2272827A1 |
| 15167-EP2272832A1 |
| 15167-EP2275420A1 |
| 15167-EP2295055A2 |
| 15167-EP2295416A2 |
| 15167-EP2295426A1 |
| 15167-EP2295427A1 |
| 15167-EP2298748A2 |
| 15167-EP2298764A1 |
| 15167-EP2298765A1 |
| 15167-EP2298778A1 |
| 15167-EP2305642A2 |
| 15167-EP2308833A2 |
| 15167-EP2308861A1 |
| 15167-EP2311453A1 |
| 15167-EP2311825A1 |
| 15167-EP2311842A2 |
| 15167-EP2316832A1 |
| 15167-EP2316833A1 |
| 2041 C. B |
| 2041 C. B. |
| 2041 C.B |
| 2041 C.B. |
| 2041CB |
| 32314-EP2280012A2 |
| 32314-EP2281815A1 |
| 32314-EP2292595A1 |
| 32314-EP2292615A1 |
| 32314-EP2301928A1 |
| 32314-EP2301933A1 |
| 32314-EP2305640A2 |
| 32314-EP2305671A1 |
| 32314-EP2311827A1 |
| 32314-EP2311840A1 |
| 4-((Methylsulfonyl)oxy)butyl methanesulfonate |
| 4-(methanesulfonyloxy)butyl methanesulfonate |
| 4-(methylsulfonyloxy)butyl methylsulfonate |
| 4-[(Methylsulfonyl)oxy]butyl methanesulfonate # |
| 4-methylsulfonyloxybutyl methanesulfonate |
| 55-98-1 |
| AB00051929_12 |
| AB00051929_14 |
| AB00051929-10 |
| AB00051929-11 |
| AB0006846 |
| AB2000224 |
| AC-198 |
| AC1L1DRQ |
| AC1Q4GRQ |
| acid, tetramethylene ester |
| ACMC-20aljs |
| AI3-25012 |
| AK307420 |
| AKOS003614975 |
| alkylating agent: crosslinks guanine residues |
| Ambap55-98-1 |
| AN 33501 |
| AN-16062 |
| BC677894 |
| Bisulfex |
| BRN 1791786 |
| BSPBio_001920 |
| Busilvex |
| busulfan |
| BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE) |
| Busulfan (JP17/USP/INN) |
| Busulfan (Myleran, Busulfex) |
| Busulfan [INN:JAN] |
| Busulfan [USP:INN:BAN:JAN] |
| Busulfan, 98% 5g |
| Busulfan, analytical standard, for drug analysis |
| Busulfan, European Pharmacopoeia (EP) Reference Standard |
| Busulfan; |
| Busulfan/Myleran |
| Busulfano |
| Busulfano [INN-Spanish] |
| Busulfanum |
| Busulfanum [INN-Latin] |
| Busulfex |
| Busulfex IV |
| Busulphan |
| Busulphane |
| butane-1,4-diyl dimethanesulfonate |
| Butanedioldimethanesulfonate |
| Buzulfan |
| C.B. 2041 |
| C06862 |
| C6H14O6S2 |
| CAS-55-98-1 |
| CB 2041 |
| CCG-35458 |
| CCRIS 418 |
| CHEBI:28901 |
| CHEMBL820 |
| Citosulfan |
| COVZYZSDYWQREU-UHFFFAOYSA- |
| COVZYZSDYWQREU-UHFFFAOYSA-N |
| CPD000058613 |
| CS-2224 |
| CTK1G9627 |
| D00248 |
| D07SUG |
| DB01008 |
| DivK1c_000847 |
| DSSTox_CID_910 |
| DSSTox_GSID_20910 |
| DSSTox_RID_75857 |
| DTXSID3020910 |
| EINECS 200-250-2 |
| FT-0083567 |
| FT-0623291 |
| G.T. 41 |
| G1LN9045DK |
| Glyzophrol |
| GT 2041 |
| GT 41 |
| GTPL7136 |
| HMS1920I07 |
| HMS2091O09 |
| HMS2233H04 |
| HMS3259G15 |
| HMS3370E11 |
| HMS3655A21 |
| HMS502K09 |
| HSDB 7605 |
| HY-B0245 |
| I09-1371 |
| IDI1_000847 |
| InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3 |
| K-9954 |
| KBio1_000847 |
| KBio2_000512 |
| KBio2_003080 |
| KBio2_005648 |
| KBio3_001420 |
| KBioGR_000698 |
| KBioSS_000512 |
| KS-000012XA |
| KS-5212 |
| Leucosulfan |
| LP056981 |
| LS-1358 |
| Mablin |
| MCULE-1840882522 |
| Methanesulfonic |
| Methanesulfonic acid, tetram ethylene ester |
| Methanesulfonic acid, tetramethylene ester |
| MFCD00007562 |
| Mielevcin |
| Mielosan |
| Mielucin |
| Milecitan |
| Mileran |
| Misulban |
| Mitosan |
| Mitostan |
| MLS001076666 |
| MolPort-001-783-406 |
| Myeleukon |
| Myeloleukon |
| Myelosan |
| Myelosanum |
| Mylecytan |
| MYLERAN (TN) |
| Myleran tablets |
| Myleran, Busulfex, Busulfan |
| Myleran;Busulfex |
| Mylerlan |
| n-Butane-1,3-di(methylsulfonate) |
| NC00498 |
| NCGC00090905-01 |
| NCGC00090905-02 |
| NCGC00090905-03 |
| NCGC00090905-04 |
| NCGC00090905-05 |
| NCGC00090905-06 |
| NCGC00090905-07 |
| NCGC00090905-08 |
| NCGC00090905-09 |
| NCGC00090905-10 |
| NCGC00090905-11 |
| NCGC00090905-12 |
| NCGC00254038-01 |
| NCGC00259397-01 |
| NCI-C01592 |
| NCI60_041640 |
| NCIMech_000192 |
| NINDS_000847 |
| NSC 750 |
| NSC-750 |
| NSC-755916 |
| NSC750 |
| NSC755916 |
| O994 |
| OR011696 |
| OR285011 |
| OR285012 |
| Pharmakon1600-01500152 |
| Prestwick_989 |
| s1692 |
| SAM002554887 |
| SBI-0051300.P003 |
| SC-22586 |
| SCHEMBL4373 |
| SMR000058613 |
| SPBio_000253 |
| Spectrum_000092 |
| SPECTRUM1500152 |
| Spectrum2_000067 |
| Spectrum3_000320 |
| Spectrum4_000259 |
| Spectrum5_000928 |
| SR-01000765405 |
| SR-01000765405-7 |
| ST45022142 |
| ST50825921 |
| Sulfabutin |
| Sulfabutin (VAN) |
| Sulphabutin |
| TC-167599 |
| Tetramethylene {bis[methanesulfonate]} |
| Tetramethylene bis(methanesulfonate) |
| Tetramethylene bis[methanesulfonate] |
| Tetramethylene dimethane sulfonate |
| Tetramethylenester kyseliny methansulfonove |
| Tetramethylenester kyseliny methansulfonove [Czech] |
| Tetramethylenester kyseliny methansulfonove[Czech] |
| Tox21_111038 |
| Tox21_111038_1 |
| Tox21_201848 |
| Tox21_300318 |
| UNII-G1LN9045DK |
| WLN: WS1&O4OSW1 |
| X 149 |
| Z276508890 |
| ZINC1530572 |
US Patents and Regulatory Information for MYLERAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspen Global Inc | MYLERAN | busulfan | INJECTABLE;INJECTION | 208536-001 | Nov 20, 2017 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Aspen Global | MYLERAN | busulfan | TABLET;ORAL | 009386-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
or, see our see our flat-rate plans
